Takeda's tetravalent dengue vaccine meets in Phase III

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) said TAK-003 met the primary endpoint in Part 1 of the Phase III TIDES (DEN-301) trial to prevent dengue fever caused by any of the four serotypes of the virus. TAK-003 is a tetravalent dengue

Read the full 417 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE